Summary The mutagenic activity of razoxane (ICRF 159) was studied using the Salmonella/microsome assay and rodent bone-marrow micronucleus and metaphase assays.
The bisdioxopiperazines are a class of antitumour agents first synthesised at the Imperial Cancer Research Fund as potential intracellularly activated chelating agents (Creighton, 1970) . The best known of these is ICRF 159 which was shown to be active against experimental tumours in rats and mice (Creighton et al., 1969) . It was subsequently developed as a drug for the treatment of certain forms of human cancer under the approved name of razoxane (Bakowski, 1976) .
The effects of razoxane on both cells in culture and tumours in vivo have been studied extensively. Abnormal chromosome condensation and inhibition of cell division were demonstrated by Sharpe et al. (1970) using cultured human lymphocytes, but only when razoxane was present at the G2/M stage of the cell cycle. This cell cycle stage specificity of the cytotoxic action of razoxane (as well as abnormal mitosis and increase in cellular DNA content) has also been demonstrated by Creighton (1979) . However, binding studies using radiolabelled razoxane have failed to show an association with any cellular macromolecules. In limited genetic toxicity assays razoxane has been reported to be nonmutagenic in the Salmonella/microsome assay but causing an increase in the mutation frequency of cultured Chinese hamster V-79A cells as well as an increase in unscheduled DNA synthesis (Witiak et al., 1979) .
In this paper the mutagenic activity of razoxane has been examined both in vitro (using the Salmonella/ microsome gene mutation assay) and in vivo (using Salmonella/microsome assay The procedure followed that of Ames et al. (1975) .
The S-9 mix was prepared from the liver of male Metaphase assay This was divided into a time-course study (to establish the time of maximal chromosome damge) and a dose-response study (at the time of maximal chromosome damage).
Time-course study Chinese hamsters (4 males/ sample time) were administered a single oral dose of 500mg kg-1 body weight razoxane (the maximum tolerated oral dose). Aqueous polysorbate 80 (0.5% w/v; 10mlkg-1 bodyweight) was used as the vehicle control and cyclophosphamide (40mgkg-1) and methotrexate (500mgkg-1) were the reference positive controls (2 males/group/sample time). At 6, 12, 24 and 48 h after dosing bone-marrow cell chromosome preparations were made using the method of Schmid et al. (1971) . The chromosome preparations were stained using 4% Giemsa (Gurrs R66) for 2min. The slides were then mounted in DPX and coded before microscopic analysis. Where possible 50 cells at the metaphase stage of the cell cycle were analysed for structural chromosome damage from each animal. Dose-response study Chinese hamsters (5/sex-/group) were administered single oral doses of 20, 50, 100 or 500mgkg-1 razoxane. Aqueous polysorbate 80 (0.5%w/v; 10mlkg-1) was used as the vehicle control. Chromosome preparations from bone-marrow cells were made 24h after dosing (the time of maximal chromosome damage -see results section) as described above.
Statistical analysis was done using Fisher's exact test (single-sided significance levels) and was restricted to the dose-response study due to the small group size in the time-course study. The incidence of chromosomally aberrant cells and polyploid cells in the razoxane-dosed animals was compared to that of the vehicle control.
Results

Salmonella/microsome assay
The mean revertant colony counts for each of the strains of Salmonella treated with razoxane are shown in Table I . These counts were similar in the presence and absence of S-9 to those of the appropriate untreated and solvent treated controls. All the positive and negative control data were within the historical and acceptable values for this laboratory.
Micronucleus assay The incidence of micronuclei for each group is shown in Table II . Only data from the 24 h sample time were analysed statistically due to cytoxicity at 48 and 72 h. At the 48 and 72 h sample times there were no deaths but there were large increases in the number of NCEs and a correspondingly large decrease in the number of PCEs in the bone-marrow of the razoxane-dosed animals which compromised an accurate micronucleus analysis (see Table II ).
At the 24h sample time, the incidence of micronucleated PCEs was increased in the razoxanedosed animals (15/4000 PCEs at 200mg kg-1 and 9/4000 PCEs at 400mg kg-1 razoxane) compared to the vehicle control (3/4000 PCEs); the increase was only statistically significant in animals dosed 200mg kg-1. In the limited data available at the 48 h sample time there was an apparent increase in the incidence of micronucleated PCEs at 400mg kg-1 razoxane (see Table II ).
Cyclophosphamide caused the expected increase in micronucleated PCEs at the 24 and 48h sample times.
Metaphase assay
The results of the time course study and the doseresponse study are summarised in Tables III and IV  respectively. Time-course study Six hours after dosing, the bone-marrow cells of the razoxane-dosed animals had abnormally condensed chromosomes (ACC). The chromosomes were elongated and had the appearance of early prophase chromsomes making an accurate assessment of structural damage difficult (see Figure 1) . At 12 and 24h chromosome condensation was normal but the incidence of chromosomally aberrant cells in the razoxane-dosed animals was increased (maximum 14.0%) compared to the vehicle control (1.4%). Maximal structural chromosome damage was observed between 12 and 24 h after dosing (see Table III and Figure 2 ). There was a large increase in polyploid cells in the razoxane-dosed group at the 24h sample time only (16.5% incidence). At 6, 12 and 48h the incidence of polyploid cells (range 0-2.5%) in the razoxanedosed group was within the historical control range for this laboratory (0-5.3%). Based on these observations a single sample time, 24h after dosing was chosen for the dose-response study. a b Dose-response study The incidence of chromosomally aberrant cells in the 100 and 500 mg kg-1 razoxane-dosed groups was statistically significantly increased (in a dose-dependent manner) compared to the vehicle control (see Table IV ). At the lower doses (20 and 50 mg kg-1 razoxane), the incidence of aberrant cells was similar to the vehicle control but the types of damage (translocations and deletions) observed were different from the vehicle control and considered to be of biological significance (see Table IV ). There was also a dosedependent, statistically significant increase in polyploid cells in the razoxane-dosed groups (range 2.2-14.9%) compared to the vehicle control (0.4%).
The incidence of polyploid cells in the 20 and 50mg kg-1 razoxane-dosed groups (2.2 and 2.4% respectively) was within the historical control range for this laboratory (0-3.5%).
Discussion
Razoxane was without effect in the Salmonella/microsome assay and mutagenic in mammalian chromosomal assays. Razoxane has previously been shown to induce both gene mutations and an increase in unscheduled DNA synthesis irk cultured mammalian cells (Witiak et al., 1977) . The combined data indicate that the mutagenic activity of razoxane is restricted to eukaryotes. The molecular mechanism by which razoxane is able to induce these aberrations in DNA remains unknown. '-0t Dawson (1975) failed to detect covalent binding of radio-labelled razoxane to cellular DNA or RNA, but the damage to DNA may be indirect. Livingstone et al. (1972) have shown that razoxane is able to bind to histone proteins in vitro. Histones are nucleoproteins which form an integral part of the eukaryotic chromosome structure. If razoxane is able to bind to histone proteins this association could have an adverse effect on DNA synthesis resulting in structural chromosome damage. Razoxane also induces abnormal chromosome condensation and the effect appears to be unique to razoxane since other anticancer agents which induce structural chromosome aberrations (e.g. cyclophosphamide and 5-fluorouracil) have no effect on chromosome condensation. Razoxane was originally synthesised as an intracellularly active (metal ion) chelating agent but this mode of action has since been questioned (Huang et al., 1982) . Chelation could explain the abnormal chromosome condensation since metal ions (eg Ca2+) are known to be involved in the complex chromosome condensation process. Alternatively the razoxane/histone association, demonstrated by Livingstone et al. (1972) , could also prevent normal chromosome condensation by disrupting the DNA chain as it begins to condense prior to mitosis. Chromosome condensation occurs at the G2/M stage of the cell cycle, the stage at which razoxane exerts its maximal cytotoxic effect (Sharpe et al., 1970; Creighton, 1974) and from these observations the mode of action appears to be specific to condensing chromatin of eukaryotes (NB prokaryotes do not undergo a DNA condensation cycle). Razoxane was also shown to affect cell division as seen by the increase in polyploid cells. Similar effects have been demonstrated in vitro using timelapse photography and cytofluorographic analysis of razoxane treated L cells by Creighton (1979) . The time-lapse photography showed abnormal cell division, i.e. as the daughter cells moved apart they often remained linked by strands of nuclear material. Eventually, the daughter cells rejoined to form a tetraploid cell or separated with uneven amounts of chromatin. The cytofluorographic analysis of the L-cells showed an increase in cellular DNA content after treatment with razoxane.
The mechanism of action of razoxane is under further investigation using closely related active and inactive analogues of razoxane (Herman et al., 1982) in cultured human lymphocytes.
